This CME/CE activity will highlight recent data for the treatment and management of acute leukemia, including information presented at the American Society of Hematology Annual Meeting in Orlando, Florida. The expert faculty, chaired by Eytan M. Stein, MD, will first discuss the pathophysiology of acute myeloid leukemia (AML) and acute lymphoblastic leukemia (ALL), reviewing diagnostic criteria and comorbidities. Current clinical trial data regarding safety and efficacy of approved therapeutics will also be reviewed and clinical relevance debated. The faculty will highlight best practices for collaborating with the interprofessional team to administer effective treatment plans. Upon completing this activity, clinicians will gain insight into how to optimally treat and manage acute leukemia patients in the modern day.
Hematologists, oncologists and other healthcare professionals who care for patients with acute leukemia
I. Acute Leukemia Update: The Pathophysiology, Diagnostic Criteria, and Associated Comorbidities
II. A Clinical Analysis of the Safety & Efficacy of Novel Therapeutic Agents for Managing Patients with AML and ALL
III. Developing Effective Treatment Plans with the Interprofessional Team to Improve the Quality of Life in Patients with AML & ALL
- Understand the pathophysiology, diagnostic criteria, and comorbidities of AML and ALL for the optimal treatment of patients
- Review safety and efficacy data from clinical trials of novel therapeutic agents for the management of patients with AML and ALL
- Collaborate with the interprofessional team to develop appropriate and effective treatment plans to improve quality of life in patients with AML and ALL
Disclosures of Conflict of Interest
It is the policy of AcademicCME that all faculty, instructors, and planners disclose real or apparent conflicts of interest relating to the topics of this educational activity.
The faculty reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CE activity:
|Faculty||Relationship Identified With:|
Eytan M. Stein, MD
|Consultant/Advisor: AbbVie Inc.; Agios Pharmaceuticals Inc.; Amgen Inc.; Astellas Pharma; Bioline; BioSight Ltd.; Celgene Corp.; Daiichi Sankyo Co, Ltd.; Novartis International AG; Syros Pharmaceuticals Inc.
Grant/Research Support: Agios Pharmaceuticals Inc.; Amgen Inc.; Bayer AG; BTX Therapeutics; Celgene Corporation; Syndax Pharmaceuticals Inc.
Stockholder: Auron Therapeutics
Jae Park, MD
|Consultant/Advisor: Amgen Inc.; Kite Pharma; Novartis International AG; Allogene Therapeutics; Incyte Corporation; Autolus Therapeutics; Intellia Therapeutics; Servier Laboratories; Artiva Biotherapeutics|
Planners and Peer Reviewers
Timothy Hayes, MD, PhD; Kim Cheramie, MSN, RN-BC; Devon Dietzel and Nicole Brestowski hereby state that they or their spouse/life partner do not have any financial relationships to products or devices with any commercial interests related to the content of this activity of any amount during the past 12 months.
In support of improving patient care, AcademicCME is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
Credit Designation Statements
AcademicCME designates this live material for a maximum of 1.0 AMA PRA Category 1 CreditTM.
This activity has been supported by an independent educational grant from Amgen Inc.
Disclosure of Unlabeled Use
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. AcademicCME and Amgen Inc. do not recommend the use of any agent outside of the labeled indications.
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.
Method of Participation
In order to claim credit, participants must complete the following:
- Read the learning objectives, accreditation information and faculty disclosures at the beginning of this activity.
- Complete the Pre-Activity Questions.
- Read or Review the activity content.
- Complete the Post-Activity Test Questions and Evaluation.
- Healthcare providers who receive a grade of 70% or better on the Post-Activity Test Questions and who complete the Evaluation will receive a CME/CNE Certificate.
- All other participants who receive a grade of 70% or better on the Post-Activity Test Questions and who complete the Evaluation will receive a Certificate of Participation.
CE Inquiries/Special Needs
For all CE inquiries or special needs, please contact [email protected].